[go: up one dir, main page]

UY35933A - Composiciones farmacéuticas que comprenden azd9291 - Google Patents

Composiciones farmacéuticas que comprenden azd9291

Info

Publication number
UY35933A
UY35933A UY0001035933A UY35933A UY35933A UY 35933 A UY35933 A UY 35933A UY 0001035933 A UY0001035933 A UY 0001035933A UY 35933 A UY35933 A UY 35933A UY 35933 A UY35933 A UY 35933A
Authority
UY
Uruguay
Prior art keywords
azd9291
pharmaceutical compositions
pharmaceutical
compositions
enamide
Prior art date
Application number
UY0001035933A
Other languages
English (en)
Inventor
Wilson David
Finnie Cindy
Steven Anthony Raw
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50191689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35933(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY35933A publication Critical patent/UY35933A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas adecuadas para la administración oral, y más particularmente a composiciones farmacéuticas, que incluyen composiciones de comprimidos farmacéuticos, que contienen N-(2-{2-dimetilaminoetil-5 metilamino}-4-metoxi-5-{[4-(1-metilindol-3-il)pirimidin-2-il]amino}fenil)prop-2-enamida (?AZD9291?) o una sal farmacéuticamente aceptable de este, donde tales composiciones comprenden una cierta cantidad de celulosa microcristalina y al menos otro diluyente farmacéutico.
UY0001035933A 2014-01-02 2014-12-29 Composiciones farmacéuticas que comprenden azd9291 UY35933A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1400034.3A GB201400034D0 (en) 2014-01-02 2014-01-02 Pharmaceutical Compositions comprising AZD9291

Publications (1)

Publication Number Publication Date
UY35933A true UY35933A (es) 2015-07-31

Family

ID=50191689

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035933A UY35933A (es) 2014-01-02 2014-12-29 Composiciones farmacéuticas que comprenden azd9291

Country Status (37)

Country Link
US (6) US10183020B2 (es)
EP (1) EP3089741B1 (es)
JP (1) JP6588915B2 (es)
KR (1) KR102336378B1 (es)
CN (2) CN105848647B (es)
AR (1) AR098989A1 (es)
AU (1) AU2015204218B2 (es)
CA (1) CA2933403C (es)
CL (1) CL2016001609A1 (es)
CR (1) CR20160310A (es)
CY (1) CY1124848T1 (es)
DK (1) DK3089741T3 (es)
DO (1) DOP2016000156A (es)
EA (1) EA034243B9 (es)
ES (1) ES2873226T3 (es)
GB (1) GB201400034D0 (es)
GT (1) GT201600142A (es)
HR (1) HRP20210749T1 (es)
HU (1) HUE054344T2 (es)
IL (1) IL246186B (es)
LT (1) LT3089741T (es)
MX (1) MX367358B (es)
MY (1) MY183536A (es)
NI (1) NI201600098A (es)
NZ (1) NZ721298A (es)
PE (1) PE20161170A1 (es)
PH (1) PH12016501310B1 (es)
PL (1) PL3089741T3 (es)
PT (1) PT3089741T (es)
RS (1) RS61927B1 (es)
SG (1) SG11201605339QA (es)
SI (1) SI3089741T1 (es)
SM (1) SMT202100330T1 (es)
TW (1) TWI702953B (es)
UY (1) UY35933A (es)
WO (1) WO2015101791A1 (es)
ZA (1) ZA201605300B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (es) 2014-01-24 2018-02-24
SG11201809751XA (en) 2016-05-26 2018-12-28 Zeno Royalties & Milestones Llc Egfr inhibitor compounds
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
CN110013468B (zh) * 2018-01-09 2022-02-18 北京福元医药股份有限公司 一种azd9291氘代衍生物药物制剂
WO2019138346A1 (en) * 2018-01-10 2019-07-18 Alembic Pharmaceuticals Limited Pharmaceutical composition of osimertinib
TW201941773A (zh) * 2018-02-12 2019-11-01 瑞典商阿斯特捷利康公司 用於治療非小細胞肺癌之奧希替尼
PL3758708T3 (pl) * 2018-03-01 2025-03-31 Astrazeneca Ab Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid
WO2019178868A1 (zh) 2018-03-23 2019-09-26 无锡双良生物科技有限公司 一种药物组合物及其制备方法和用途
EP3823627A4 (en) 2018-07-17 2022-04-20 Insmed Incorporated CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
MX2021011810A (es) 2019-03-29 2021-10-26 Astrazeneca Ab Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TW202304457A (zh) * 2021-03-22 2023-02-01 瑞典商阿斯特捷利康公司 配製物
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
CA3249080A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
KR20250029133A (ko) 2022-06-27 2025-03-04 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물
CN119654152A (zh) 2022-07-08 2025-03-18 阿斯利康(瑞典)有限公司 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
WO2025092926A1 (zh) * 2023-10-31 2025-05-08 浙江同源康医药股份有限公司 一种嘧啶类衍生物的药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
WO2001076565A1 (fr) * 2000-04-12 2001-10-18 Banyu Pharmaceutical Co., Ltd. Compositions et preparations se desintegrant dans la cavite buccale
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
KR101002374B1 (ko) 2002-02-26 2010-12-17 아스트라제네카 아베 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
US20080102133A1 (en) * 2004-10-05 2008-05-01 Antje Brueck-Scheffler Oral Pharmaceutical Preparation for Proton Pump Antagonists
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
TW200800181A (en) * 2006-02-09 2008-01-01 Sankyo Co Pharmaceutical composition for anticancer
JP5576922B2 (ja) * 2006-04-20 2014-08-20 信越化学工業株式会社 腸溶性固体分散体を含んでなる固形製剤
EP2170062A4 (en) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
WO2012139736A1 (en) 2011-04-11 2012-10-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical composition comprising bosentan
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
PT3009431T (pt) * 2011-07-27 2017-12-26 Astrazeneca Ab Compostos de 2-(2,4,5-anilino-substituídos)pirimidina como moduladores úteis do egfr para o tratamento do cancro
ES2946549T3 (es) * 2012-01-13 2023-07-20 Xspray Pharma Ab Publ Composición farmacéutica de nilotinib
WO2013160916A1 (en) 2012-04-25 2013-10-31 Hetero Research Foundation Sunitinib malate solid dispersion
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291

Also Published As

Publication number Publication date
HRP20210749T1 (hr) 2021-06-25
CN114712362A (zh) 2022-07-08
CA2933403C (en) 2022-03-29
SG11201605339QA (en) 2016-07-28
US20220395502A1 (en) 2022-12-15
SI3089741T1 (sl) 2021-08-31
AR098989A1 (es) 2016-06-22
HUE054344T2 (hu) 2021-08-30
US20190111057A1 (en) 2019-04-18
IL246186A0 (en) 2016-07-31
TWI702953B (zh) 2020-09-01
AU2015204218A1 (en) 2016-07-07
MX367358B (es) 2019-08-16
CN105848647A (zh) 2016-08-10
RS61927B1 (sr) 2021-06-30
CN105848647B (zh) 2022-04-26
EA034243B9 (ru) 2020-04-10
JP6588915B2 (ja) 2019-10-09
HK1225655A1 (zh) 2017-09-15
DK3089741T3 (da) 2021-06-07
JP2017501201A (ja) 2017-01-12
US20200360378A1 (en) 2020-11-19
PH12016501310B1 (en) 2022-07-06
ES2873226T3 (es) 2021-11-03
PH12016501310A1 (en) 2016-09-14
TW201609101A (zh) 2016-03-16
MX2016008744A (es) 2016-09-08
GT201600142A (es) 2019-08-12
WO2015101791A1 (en) 2015-07-09
KR20160101720A (ko) 2016-08-25
US20250017930A1 (en) 2025-01-16
NZ721298A (en) 2017-10-27
GB201400034D0 (en) 2014-02-19
EP3089741A1 (en) 2016-11-09
IL246186B (en) 2020-07-30
EA201691242A1 (ru) 2016-12-30
CY1124848T1 (el) 2022-11-25
CR20160310A (es) 2016-09-23
CL2016001609A1 (es) 2016-12-09
PT3089741T (pt) 2021-06-11
US20160324854A1 (en) 2016-11-10
MY183536A (en) 2021-02-25
EP3089741B1 (en) 2021-03-10
SMT202100330T1 (it) 2021-07-12
PL3089741T3 (pl) 2021-09-27
CA2933403A1 (en) 2015-07-09
KR102336378B1 (ko) 2021-12-08
DOP2016000156A (es) 2016-08-15
US20240189310A1 (en) 2024-06-13
LT3089741T (lt) 2021-06-10
PE20161170A1 (es) 2016-11-24
EA034243B1 (ru) 2020-01-21
AU2015204218B2 (en) 2017-06-15
NI201600098A (es) 2016-12-20
ZA201605300B (en) 2022-10-26
US10183020B2 (en) 2019-01-22

Similar Documents

Publication Publication Date Title
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2018009175A (es) Agonista fxr derivado de esteroides.
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201890532A1 (ru) Новые аннелированные бензамиды
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
MX2017010429A (es) Acido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilami no)-2-hidroximetil-2-metilpentanoico.
WO2016142821A3 (en) Compositions containing a thrombin inhibitor
MX2017010666A (es) Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico.
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
BR112017004694A2 (pt) composições farmacêuticas compreendendo alpelisibe
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
CO2017004382A2 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
EA201890477A1 (ru) Инкапсулированная композиция финголимода
WO2016020408A3 (en) Compounds for preventing ototoxicity
IN2014MU00859A (es)
BR112016024236A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211230